Skip to main content
OpenTrials
Completed

NCT Number: NCT05619042

Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms

The goal of this observational study is to determine the diagnostic accuracy of peripheral whole blood transcriptomes analyzed by an artificial intelligence algorithm to detect the presence and extent of coronary calcification in individuals without a history of known cardiovascular disease.

The main question it aims to answer is:

1. Will the proposed method predict the presence and extent of coronary artery calcification from the peripheral whole-blood transcriptomes?

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study will be a prospective observational single-site study. A convenience sample will be carried out to include 800 patients who attend the Clinic, to undergo a cardiac CT without contrast (coronary calcium score), either for a medical indication or volunteers for an assessment of cardiovascular risk. The study will have a baseline stage in which a clinical evaluation will be performed, blood samples will be drawn for transcriptome analysis and laboratory analysis. Then, a DNA sample obtained by swabbing the buccal mucosa will be taken. Subsequently, a non-contrast gated cardiac CT will be performed to assess the presence and extent of coronary calcification and other outcomes of interest. At the end of patient enrollment, biological samples will be sequenced for in silico evaluation of the results. Finally, a 5-year clinical (telephone) follow-up will be carried out to collect data on the incidence of fatal and non-fatal cardiovascular events.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women between 30 and 75 years attending the institution for a non-contrast cardiac CT scan (coronary calcium score) either by medical indication or voluntary for cardiovascular risk assessment.
  • Signature of the informed consent form

Exclusion criteria

  • Previously known chronic renal or hepatic insufficiency.
  • Active chronic lung disease, defined as exacerbated asthma, exacerbated chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.
  • Active and/or previous cardiovascular disease, defined as previous acute myocardial infarction, stable or unstable angina, cerebrovascular accident, history of vascular interventions (coronary or another territory), heart failure, severe cardiomyopathies, or valvulopathies.
  • Uncontrolled hyper or hypothyroidism.
  • Suprarenal insufficiency.
  • Previous surgeries in the last 3 months.
  • Severe trauma in the last 6 months, defined as one that involved bone fractures and/or surgical interventions.
  • Known active cancer disease or under treatment (acute or preventive), or history of cancer disease without criteria for a cure.
  • Known autoimmune disease active or in treatment.
  • Ongoing pregnancy, postpartum period of fewer than 12 months, or breastfeeding.
  • Other serious illnesses with an estimated life expectancy of fewer than 12 months (according to the investigators).
  • Temperature greater than 37.5°C recorded by a thermometer or any acute infection caused by viruses or bacteria confirmed by a health professional in the previous 30 days.
  • Pathologies under immunosuppressive treatment

Treatment and study plan

Primary outcomes

  1. Coronary artery calcium score

    Time frame: At baseline (cross-sectional assessment)

    Coronary artery calcium (CAC) score (Agatston units) stratified with increasing risk according to the Society of Cardiovascular Computed Tomography Guidelines as CAC=0; CAC 1-99; CAC 100-299; and CAC≥300.

Secondary outcomes

  1. Coronary artery calcium score

    Time frame: At baseline (cross-sectional assessment)

    Percentile Agatston score: according to age and sex with a increasing risk ranging from 1 to 99 th percentile.

  2. Coronary artery calcium score (number of segments)

    Time frame: At baseline (cross-sectional assessment)

    Number of segments with coronary calcifications ranging from 0 to 17 segments.

  3. Aortic valve calcium

    Time frame: At baseline (cross-sectional assessment)

    Aortic valve calcification score (Agatston units) as a continuous variable with increasing risk and without preestablished thresholds

  4. Thoracic aorta calcium

    Time frame: At baseline (cross-sectional assessment)

    Thoracic aorta calcification score (Agatston units) as a continuous variable with increasing risk and without preestablished thresholds

  5. Epicardial adipose tissue (volume)

    Time frame: At baseline (cross-sectional assessment)

    cm2/m2

  6. Epicardial adipose tissue (density)

    Time frame: At baseline (cross-sectional assessment)

    density, Q1-Q4: quartiles percentage

  7. Fatty liver

    Time frame: At baseline (cross-sectional assessment)

    liver attenuation <48 Hounsfield units

  8. Neutrophil to lymphocyte ratio

    Time frame: At baseline (cross-sectional assessment)

    hematological parameter for systemic inflammation and stress

  9. High-sensitive C reactive protein (CRP)

    Time frame: At baseline (cross-sectional assessment)

    mg/dl

  10. Repolarization abnormalities

    Time frame: At baseline (cross-sectional assessment)

    Number of participants with repolarization abnormalities on a 12-lead ECG, defined as ST segment depression or pathological T wave inversion.

  11. Left ventricular hypertrophy

    Time frame: At baseline (cross-sectional assessment)

    Number of participants with left ventricular hypertrophy on a 12-lead ECG, defined by positive Sokolow-Lyon or Cornell criteria.

  12. Intraventricular conduction abnormalities

    Time frame: At baseline (cross-sectional assessment)

    Number of participants with intraventricular conduction abnormalities on a 12-lead ECG, stratified by the presence of left bundle branch

    block; right bundle branch block and left posterior fascicular block; right bundle branch block and left anterior fascicular block or right bundle branch block; or left anterior fascicular block.

  13. Percent electron density relative to water (%EDW)

    Time frame: At baseline (cross-sectional assessment)

    percent electron density relative to water, available for direct evaluation with dedicated software in all scans acquired using a dual-layer spectral CT scanner).

  14. Death

    Time frame: year 1 through 5

    Number of participants with report of death from any cause

  15. Acute ischemic syndrome

    Time frame: year 1 through 5

    Number of participants with non fatal diagnosis of acute myocardial infarction or unstable angina

  16. Heart failure

    Time frame: year 1 through 5

    Number of participants with non fatal new diagnosis of heart failure with preserved or impaired ventricular function

  17. Vascular revascularization

    Time frame: year 1 through 5

    Number of participants with performance of myocardial revascularization surgery, coronary angioplasty or peripheral vascular angioplasty

  18. cerebrovascular event

    Time frame: year 1 through 5

    Number of participants with non fatal diagnosis of cerebrovascular accident ("stroke") or transient ischemic attack

  19. Cancer

    Time frame: year 1 through 5

    Number of participants with new diagnosis of any type of cancer

Sponsors and collaborators

Lead sponsor

Santiago Gabriel Miriuka

Other

Collaborators

  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia

Registry information

Official study title

Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms. (CAC-TRAIT Study)

Acronym: CAC-TRAIT

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Nov 16, 2022
Registry last updated
Mar 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.